Riskpilot← Back to searchSign inGet full accessAcureOmics AB
ABActiveOrg 5593555260Oxbärsvägen 20Research and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
+61% vs 2023
Equity ratio
15.3%
Financial strength
Net profit 2024
SEK -3K
+64% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -3K | +61% |
| Net profit | SEK -3K | +64% |
| Total assets | SEK 33K | +39% |
| Equity | SEK 5K | -38% |
| Employees | 0 | — |
Legal name
AcureOmics AB
Org number
5593555260
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 december 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
AcureOmics AB erbjuder tjänster och projektledning inom metabolit profilering (metabolomics) riktat mot individualiserad behandling för ökad livskvalité.
Address
Oxbärsvägen 20
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −8 | −9 | −3 |
| Depreciation & amort. | — | — | — |
| EBIT | −8 | −9 | −3 |
| Net financials | 0 | 0 | 0 |
| Profit before tax | −8 | −9 | −3 |
| Tax | — | — | — |
| Net profit | −8 | −9 | −3 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 24 | 24 | 33 |
| Equity | 17 | 8 | 5 |
| Long-term debt | — | — | — |
| Short-term debt | 7 | 16 | 28 |
| Total debt | 7 | 16 | 28 |
EBITDA margin
-346600.0%
This company
15.8%
Market median
-2193771% vs market
20222024
Equity ratio
15.3%
This company
38.2%
Market median
-60% vs market
20222024
Return on equity
-61.6%
This company
18.4%
Market median
-435% vs market
20222024
Net profit margin
-311000.0%
This company
8.1%
Market median
-3839606% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
5.53×
This company
0.62×
Market median
-792% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-12-20 – 2022-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AcureOmics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Theodor Trygg | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Board of Directors | 0 companies |
| Lars Hugo Viking Rillner | Deputy Board Member | 0 companies |
| Rolf Allan Trygg | Deputy Board Member | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Mikaela Jenni Berglund | Deputy Board Member | 0 companies |
| Nils Johan Trygg | Board of Directors | 0 companies |